In a new study, scientists have adapted a chemical approach to turn diseased cells into unique manufacturing sites for molecules that can treat a form of muscular dystrophy.
In general, small, low molecular weight compounds can pass the blood-brain barrier, while larger, higher weight compounds tend to be more potent. In the new study, however, small molecules became powerful inhibitors when they bound to targets in cells expressing an RNA defect, such as those found in myotonic dystrophy.
Myotonic dystrophy type 2, a relatively mild and uncommon form of the progressive muscle weakening disease, is caused by a type of RNA defect known as a “tetranucleotide repeat,” in which a series of four nucleotides is repeated more times than normal in an individual’s genetic code. In this case, a cytosine-cytosine-uracil-guanine (CCUG) repeat binds to the protein MBNL1, rendering it inactive and resulting in RNA splicing abnormalities that, in turn, results in the disease.
“We’re using a cell as a reaction vessel and a disease-causing defect as a catalyst to synthesize a treatment in a diseased cell,” said TSRI Professor Matthew Disney. “Because the treatment is synthesized only in diseased cells, the compounds could provide highly specific therapeutics that only act when a disease is present. This means we can potentially treat a host of conditions in a very selective and precise manner in totally unprecedented ways.”
Targeting RNA Repeats
In the study, a pair of small molecule “modules” the scientists developed binds to adjacent parts of the defect in a living cell, bringing these groups close together. Under these conditions, the adjacent parts reach out to one another and, as Disney describes it, permanently hold hands. Once that connection is made, the small molecule binds tightly to the defect, potently reversing disease defects on a molecular level.
“When these compounds assemble in the cell, they are 1,000 times more potent than the small molecule itself and 100 times more potent than our most active lead compound,” said Research Associate Suzanne Rzuczek, the first author of the study. “This is the first time this has been validated in live cells.”
Click Chemistry Construction
The basic process used by Disney and his colleagues is known as “click chemistry”—a process invented by Nobel laureate K. Barry Sharpless, a chemist at TSRI, to quickly produce substances by attaching small units or modules together in much the same way this occurs naturally.
“In my opinion, this is one unique and a nearly ideal application of the process Sharpless and his colleagues first developed,” Disney said.
Given the predictability of the process and the nearly endless combinations, translating such an approach to cellular systems could be enormously productive, Disney said. RNAs make ideal targets because they are modular, just like the compounds for which they provide a molecular template.
Not only that, he added, but many similar RNAs cause a host of incurable diseases such as ALS (Lou Gehrig’s Disease), Huntington’s disease and more than 20 others for which there are no known cures, making this approach a potential route to develop lead therapeutics to this large class of debilitating diseases.
Citation: Suzanne G. Rzuczek, Dr. HaJeung Park, Matthew D. Disney, A Toxic RNA Catalyzes the In Cellulo Synthesis of Its Own Inhibitor, Angewandte Chemie, 27 AUG 2014 DOI: 10.1002/anie.201406465
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- Great Earthquakes Doubled In The Most Recent 10 Year Period - What That Means
- What Americans Fear Most Isn't Ebola Or Terrorism, It's...
- Why Climate 'Uncertainty' Is No Excuse For Doing Nothing
- ECFA Workshop: Planning For The High Luminosity LHC
- Moderate Pot Use By Adolescents Doesn't Hurt IQ
- Cosmic Rays Jeopardize Deep-Space Astronaut Missions
- Dams Are Not The Smart Way To Secure Water For Agriculture
- "Nah. It's not free for the iPhone/iPad/iPod Touch. Apple products usually don't play nice with..."
- "http://www.cdc.gov/vaccinesafety/vaccines/HPV/index.html says no interesting difference in side..."
- "Tommaso, I fully agree with you that for the moment it would be unwise and unjustified to committ..."
- "Chaos, thanks, I couldn't come up with the word. Well, sure. The article really didn't work to..."
- "So many decisions seem to be made by ISEBYs — in someone else’s back yard. ..."
- Beyond universal donors, some poeple are programed with no blood type at all
- Anti-conventional ag movement spurs Big Ag to look to organic pesticides
- Can people really inherit memories?
- An end to fat shaming? The 50 year DNA mystery of metabolic dysfunction may soon be solved
- Egg freezing: a smart career move?
- Women carry fetal DNA long after children’s birth
- Early palliative care can cut hospital readmissions for cancer patients
- Criminologists try to solve murder mystery: Who will become a killer?
- Researchers record sight neurons in jumping spider brain
- Research suggests team-based care is most effective way to control hypertension
- UNC scientists discover hidden subpopulation of melanoma cells